Education
About Us
Working with TipRanks
Follow Us
Clene (CLNN)
NASDAQ:CLNN
CLNN Stock Chart & Stats
$5.77
-$0.20(-3.40%)
At close: 4:00 PM EST
$5.77
-$0.20(-3.40%)
Day’s Range― - ―
52-Week Range$2.28 - $13.50
Previous CloseN/A
Volume48.08K
Average Volume (3M)258.55K
Market Cap
$59.63M
Enterprise Value$75.35M
Total Cash (Recent Filing)$7.92M
Total Debt (Recent Filing)$21.31M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Mar 30, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding10,333,980
10 Day Avg. Volume504,276
30 Day Avg. Volume258,549
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-4.17
Price to Sales (P/S)107.97
P/FCF Ratio-1.73
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue352.11
Enterprise Value/Gross Profit428.14
Enterprise Value/Ebitda-2.84
Forecast
1Y Price Target
$30.40Price Target Upside426.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.3
Revenue Forecast (FY)$191.00K
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsClene reported positive results from its FDA-recommended biomarker data analysis that suggest CNM-Au8 should qualify for accelerated approval with the FDA.
FDA Approval ProcessCNM-Au8 has Orphan Drug Designation which should qualify for Priority Review, potentially leading to a faster approval process.
Market PotentialCNM-Au8's favorable safety and tolerability could be a significant factor that drives adoption and use assuming FDA approval.
Bears Say
Clene News
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $2.28 and its highest was $13.50 in the past 12 months.
What is Clene’s market cap?
Clene’s market cap is $59.63M.
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is Mar 30, 2026 which is in 111 days.
How were Clene’s earnings last quarter?
Clene released its earnings results on Nov 13, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.58 by -$0.27.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -0.55.
How many shares outstanding does Clene have?
Clene has 10,333,980 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.58. Following the earnings report the stock price went down -22.423%.
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
Clene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.40 (426.86% Upside)
$30.40 (426.86% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 43.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.33%
Trailing 12-Months
Company Description
Clene
Clene Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for neurodegenerative diseases. The company specializes in the research and commercialization of its proprietary platform technology, which utilizes nanotechnology to create therapeutics aimed at treating conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Clene operates within the biotechnology sector, concentrating on advanced drug development and clinical trials to bring new treatment options to patients in need.
CLNN Stock 12 Month Forecast
Average Price Target
$30.40
▲(426.86% Upside)
Technical Analysis
Dyadic International
―
Akari Therapeutics
―
Estrella Immunopharma
―
AN2 Therapeutics, Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
73.28% Insiders
2.44% Mutual Funds
3.50% Other Institutional Investors
19.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---